Sitaxsentan: Phase IIa

In an open label 12-week U.S. trial of 20 patients with pulmonary arterial hypertension, sitaxsentan treatment improved mean walk time distance by 10.3 percent (p=0.0062) and significantly reduced mean pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR). Adverse events included nasal congestion, abnormal coagulation parameters, flushing, headaches, edema, and anemia. In a separate open label 2-week U.S. trial in 30 patients with mild to moderate essential hypertension, 3 different doses of sitaxsentan significantly reduced blood pressure compared to baseline with no increase in heart rate. ...